30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
This study has been completed.
First Posted: August 17, 2010
Last Update Posted: October 20, 2014
Eli Lilly and Company
Information provided by (Responsible Party):